Alzheimer's Disease: Latest in Diagnosis, Biomarkers, and Anti-Amyloid Therapies

Understanding Cognitive Decline

• 🧠 Normal cognitive aging involves mild memory and attention changes that are a nuisance but don't affect daily activities or are noticeable to others.
• ⚠️ Dementia is an umbrella term for cognitive changes significantly impacting a person's activities and abilities.
• 🧩 Mild Cognitive Impairment (MCI) falls between normal aging and dementia, characterized by cognitive concerns and objective impairment on testing, but with preserved independence.

Diagnosing Alzheimer's Disease

• 🩺 Clinical evaluation for suspected Alzheimer's involves detailed history, cognitive testing (MMSE, MoCA), and assessing functional impairment.
• 📉 Key indicators include subjective memory complaints, repeating questions, misplacing items, and deficits in delayed recall on cognitive tests.
• 🔬 Neuroimaging (MRI) is crucial to rule out vascular disease and identify atrophy in areas like the mesial temporal lobes, suggestive of Alzheimer's.

Plasma Biomarkers in Alzheimer's

• 💡 Blood-based biomarkers like p-tau217 and amyloid beta ratios are emerging as screening tools for Alzheimer's pathology.
• ⚠️ These tests are only indicated for individuals with objective cognitive impairment (MCI or early dementia), not for the "worried well."
• ❓ Interpretation of these new biomarkers is still evolving, and they are best used in conjunction with clinical judgment and specialist consultation.

Anti-Amyloid Therapies: Risks and Benefits

• 🚀 Anti-amyloid therapies (e.g., lecanemab, donanemab) aim to remove amyloid plaques from the brain, showing potential to slow cognitive and functional decline.
• ⚠️ Amyloid-Related Imaging Abnormalities (ARIA), including edema (ARIA-E) and hemorrhage (ARIA-H), are significant risks, necessitating regular MRI monitoring.
• 🧬 APOE ε4 genotype testing is crucial, as homozygous APOE ε4 carriers have a substantially higher risk of ARIA and may be considered ineligible for treatment.
• ⚖️ The decision to pursue treatment involves carefully weighing the potential benefits against the risks, considering individual patient factors, comorbidities, and the evolving data on efficacy and long-term outcomes.

Treatment and Monitoring

• 📈 Early intervention is key, with benefits appearing more pronounced in earlier stages of the disease.
• 🔄 Following an initial treatment course (e.g., 18 months), maintenance therapy may be recommended, potentially with subcutaneous injections for convenience.
• 🩺 Ongoing monitoring includes regular MRIs to detect ARIA and assessing cognitive and functional status to guide treatment decisions and future management.
• 🤔 The field is rapidly evolving, with ongoing research into preclinical Alzheimer's treatments and new models of care.